Anti-TNF agents do not raise cancer risk in arthritis patientsFinding reassuring since class of drugs has mandated warning on labels about potential risk of cancer Adding rituximab to other biologics may be safe in rheumatoid arthritisIn an open-label study to investigate the safety of combining biologic agents in the treatment of rheumatoid arthritis, researchers found little serious risk when rituximab (Rituxan) was added to other drugs. Clinical Notes: Orlistat safety questioned Risk of acute kidney injury increased within one year of starting the antiobesity drug orlistat, study finds. Vimovo: first NSAID–PPI combo now available in Canada AstraZeneca introducing first fixed-dose combination product containing a nonsteroidal anti-inflammatory drug and proton pump inhibitor. NHP Forum: Preventing and treating osteoporosis Exploring natural options for the treatment of osteoporosis. Early treatment improves outcomes in rheumatoid arthritis Methotrexate-prednisone combo achieves remission in nearly two-thirds of patients Rheumatoid arthritis biologics may provoke shingles outbreaks Researchers advise clinicians to be vigilant when prescribing anti-TNF therapy Vitamin D fails to relieve knee osteoarthritis pain Impotency drug cures Raynaud’s fingertip ulcers Vaccinations not linked to rheumatoid arthritis First Previous 16 17 18 19 20 Next Last
